His admission raises new concerns about a possible upcoming wave of reckless stem cell deregulation from this administration.

Omada Health, a digital health company for 14 years supporting chronic disease patients, is yet to generate profits.

Trump health officials signal eased FDA rules for rare disease gene therapy, but concerns linger over safety, oversight, and ...

The NIH archives of the Human Genome Project could fall victim to Trump administration cuts, writes a former archivist.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

From STAT’s Adam Feuerstein: Another example of why biotech is a tough business.

It looks like the NIH is thinking about AI differently than the FDA, who earlier this week released a “rushed” AI tool across ...

HHS Secretary Robert F. Kennedy Jr. said that the FDA would look for ways to fast-track approval for rare disease treatments ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

An Otsuka drug succeeded in a Phase 3 study in a chronic kidney disease, with results that outperformed a competitor's recent ...

WASHINGTON — President Trump declared Medicare off-limits several months ago, but Republicans are now considering ways to ...